Structure via PubChem · Public domain (PubChem)
bremelanotide
Sign in to saveChemical data
- Formula
- C50H68N14O10
- Molecular weight
- 1025.2 g/mol
- IUPAC name
- (3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxylic acid
- SMILES
- CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C
- InChIKey
- FFHBJDQSGDNCIV-MFVUMRCOSA-N
- XLogP
- 0.7
- Polar surface area
- 379 Ų
- H-bond donors
- 13
- H-bond acceptors
- 12
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Protein
- First approval
- 2019
- Admin. routes
- parenteral
- Indications
- sexual dysfunction, Nausea, kidney disease
via ChEMBL · EBI
Research
106 papers- Bremelanotide.2012
- Bremelanotide: First Approval.Drugs · 2019
- Bremelanotide.2006
- Bremelanotide for Treatment of Female Hypoactive Sexual Desire.Neurology international · 2022
- Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder.The Annals of pharmacotherapy · 2020
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 1024.524
- Has use
- medication
Show 3 more facts
- chemical formula
- C₅₀H₆₈N₁₄O₁₀
- isomeric SMILES
- CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C
- canonical SMILES
- CCCCC(C(=O)NC1CC(=O)NCCCCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C
Sources (1)
via Wikidata · CC0
~12 min read
Encyclopedic overview
11 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Interactions
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Chemistry
- History
- See also
- References
{{Drugbox | Verifiedfields = verified | Watchedfields = verified | verifiedrevid = 445399889 | image = Bremelanotide structure.svg | image_class = skin-invert-image | width = 250 | alt = | pronounce = | tradename = Vyleesi | Drugs.com = | MedlinePlus = a619054 | licence_CA = | licence_EU = | DailyMedID = Bremelanotide | licence_US = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = Subcutaneous | class = Melanocortin receptor agonist | ATCvet = | ATC_prefix = G02 | ATC_suffix = CX05 | ATC_supplemental = | legal_AU = | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = | legal_CA_comment = | legal_DE = | legal_DE_comment = | legal_NZ = | legal_NZ_comment = | legal_UK = | legal_UK_comment = | legal_US = Rx-only | legal_US_comment = | legal_UN = | legal_UN_comment = | legal_status =
| bioavailability = : ~100% | protein_bound = 21% | metabolism = Hydrolysis of peptide bonds | metabolites = | onset = | elimination_half-life = 2.7 hours | duration_of_action = | excretion = Urine: 64.8%Feces: 22.8%
Excerpted from Wikipedia’s “bremelanotide” article, available under the CC BY-SA 4.0 licence.